Biofrontera submits application for FDA approval of new BF-RhodoLED® XL lamp
March 31, 2021 03:40 ET
|
Biofrontera AG
Leverkusen, Germany, March 31, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced the...
Biofrontera submits study report of pharmacokinetics study to FDA
February 24, 2021 08:30 ET
|
Biofrontera AG
Leverkusen, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces the...
Biofrontera announces preliminary revenue figures for the full year 2020
January 08, 2021 09:35 ET
|
Biofrontera AG
Leverkusen, Germany, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Biofrontera AG: Receives reasons from the Federal Court of Justice for overturning ruling of the Cologne Higher Regional Court
October 14, 2020 04:30 ET
|
Biofrontera AG
Leverkusen, Germany, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, had announced on...
Biofrontera announces conference call to be held on August 27, 2020 to discuss half-year 2020 financial results
August 19, 2020 04:30 ET
|
Biofrontera AG
Leverkusen, Germany, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Capital measure oversubscribed: Placement of the 1.00 % qualified subordinated mandatory convertible bond 2020/2021
August 18, 2020 05:00 ET
|
Biofrontera AG
Leverkusen, Germany, Aug. 18, 2020 (GLOBE NEWSWIRE) -- In a press release dated July 27, 2020, Biofrontera AG (shares of Biofrontera AG ISIN: DE0006046113) announced the issuance of up to 2,638,150...
Biofrontera dismisses case against DUSA Pharmaceuticals, Inc. in California state court
May 13, 2020 04:00 ET
|
Biofrontera AG
Leverkusen, Germany, May 13, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or “Biofrontera”), an international biopharmaceutical company, today...
Biofrontera entered into binding term sheet with Maruho Co., Ltd.
March 03, 2020 06:00 ET
|
Biofrontera AG
Leverkusen, Germany, March 03, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), an international biopharmaceutical company, announces that it has entered...
Biofrontera provides clinical development updates
February 19, 2020 05:45 ET
|
Biofrontera AG
Leverkusen, Germany, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today provides an...
Biofrontera announces 1-year follow-up results for its phase III study of photodynamic therapy for actinic keratosis on the extremities and trunk/neck
January 14, 2020 00:30 ET
|
Biofrontera AG
Leverkusen, Germany, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced...